Condition: Biliary Tract Cancer · Breast Cancer · Cervical Cancer · Sponsor: ModeX Therapeutics, An OPKO Health Company
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Email recommended · (857) 233-9936 · info@modextx.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute | Denver, Colorado, United States | Recruiting |
| Sylvester Comprehensive Cancer Center - University of Miami Health System | Miami, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06239194